<!DOCTYPE PubmedArticleSet PUBLIC "-//NLM//DTD PubMedArticle, 1st January 2019//EN" "https://dtd.nlm.nih.gov/ncbi/pubmed/out/pubmed_190101.dtd">
<PubmedArticleSet>
  <PubmedArticle>
    <MedlineCitation Status="MEDLINE" Owner="NLM" IndexingMethod="Automated">
      <PMID Version="1">35416690</PMID>
      <DateCompleted>
        <Year>2022</Year>
        <Month>05</Month>
        <Day>19</Day>
      </DateCompleted>
      <DateRevised>
        <Year>2022</Year>
        <Month>05</Month>
        <Day>19</Day>
      </DateRevised>
      <Article PubModel="Print-Electronic">
        <Journal>
          <ISSN IssnType="Electronic">1098-5530</ISSN>
          <JournalIssue CitedMedium="Internet">
            <Volume>204</Volume>
            <Issue>5</Issue>
            <PubDate>
              <Year>2022</Year>
              <Month>May</Month>
              <Day>17</Day>
            </PubDate>
          </JournalIssue>
          <Title>Journal of bacteriology</Title>
          <ISOAbbreviation>J Bacteriol</ISOAbbreviation>
        </Journal>
        <ArticleTitle>The Atypical Antipsychotic Quetiapine Promotes Multiple Antibiotic Resistance in Escherichia coli.</ArticleTitle>
        <Pagination>
          <StartPage>e0010222</StartPage>
          <MedlinePgn>e0010222</MedlinePgn>
        </Pagination>
        <ELocationID EIdType="pii" ValidYN="Y">e00102-22</ELocationID>
        <ELocationID EIdType="doi" ValidYN="Y">10.1128/jb.00102-22</ELocationID>
        <Abstract>
          <AbstractText>Atypical antipsychotic (AAP) medication is a critical tool for treating symptoms of psychiatric disorders. While AAPs primarily target dopamine (D2) and serotonin (5HT2A and 5HT1A) receptors, they also exhibit intrinsic antimicrobial activity as an off-target effect. Because AAPs are often prescribed to patients for many years, a potential risk associated with long-term AAP use is the unintended emergence of bacteria with antimicrobial resistance (AMR). Here, we show that exposure to the AAP quetiapine at estimated gut concentrations promotes AMR in Escherichia coli after 6 weeks. Quetiapine-exposed isolates exhibited an increase in MICs for ampicillin, tetracycline, ceftriaxone, and levofloxacin. By whole-genome sequencing analysis, we identified mutations in genes that confer AMR, including the repressor for the multiple antibiotic resistance <i>mar</i> operon (<i>marR</i>), and real-time reverse transcription-quantitative PCR (RT-qPCR) analysis showed increased levels of <i>marA</i>, <i>acrA</i>, and <i>tolC</i> mRNAs and reduced levels of <i>ompF</i> mRNA in the isolates carrying <i>marR</i> mutations. To determine the contribution of each <i>marR</i> mutation to AMR, we constructed isogenic strains carrying individual mutant <i>marR</i> alleles in the parent background and reevaluated their resistance phenotypes using MIC and RT-qPCR assays. While <i>marR</i> mutations induced robust activity of the <i>mar</i> operon, they resulted in only modest increases in MICs. Interestingly, although these <i>marR</i> mutations did not fully recapitulate the AMR phenotype of the quetiapine-exposed isolates, we show that <i>marR</i> mutations promote growth fitness in the presence of quetiapine. Our findings revealed an important link between the use of AAPs and AMR development in E. coli. <b>IMPORTANCE</b> AAP medication is a cornerstone in the treatment of serious psychiatric disease. The AAPs are known to exhibit antimicrobial activity; therefore, a potential unintended risk of long-term AAP use may be the emergence of AMR, although such risk has received little attention. In this study, we describe the development of multidrug antibiotic resistance in Escherichia coli after 6 weeks of exposure to the AAP quetiapine. Investigation of mutations in the <i>marR</i> gene, which encodes a repressor for the multiple antibiotic resistance (<i>mar</i>) operon, reveals a potential mechanism that increases the fitness of E. coli in the presence of quetiapine. Our findings establish a link between the use of AAPs and AMR development in bacteria.</AbstractText>
        </Abstract>
        <AuthorList CompleteYN="Y">
          <Author ValidYN="Y">
            <LastName>Kyono</LastName>
            <ForeName>Yasuhiro</ForeName>
            <Initials>Y</Initials>
            <AffiliationInfo>
              <Affiliation>Department of Pharmacy Practice, College of Pharmacy, University of Illinois Chicago, Chicago, Illinois, USA.</Affiliation>
            </AffiliationInfo>
          </Author>
          <Author ValidYN="Y">
            <LastName>Ellezian</LastName>
            <ForeName>Lori</ForeName>
            <Initials>L</Initials>
            <AffiliationInfo>
              <Affiliation>Department of Pharmacy Practice, College of Pharmacy, University of Illinois Chicago, Chicago, Illinois, USA.</Affiliation>
            </AffiliationInfo>
          </Author>
          <Author ValidYN="Y">
            <LastName>Hu</LastName>
            <ForeName>YueYue</ForeName>
            <Initials>Y</Initials>
            <AffiliationInfo>
              <Affiliation>Department of Pharmacy Practice, College of Pharmacy, University of Illinois Chicago, Chicago, Illinois, USA.</Affiliation>
            </AffiliationInfo>
          </Author>
          <Author ValidYN="Y">
            <LastName>Eliadis</LastName>
            <ForeName>Kanella</ForeName>
            <Initials>K</Initials>
            <AffiliationInfo>
              <Affiliation>Department of Pharmacy Practice, College of Pharmacy, University of Illinois Chicago, Chicago, Illinois, USA.</Affiliation>
            </AffiliationInfo>
          </Author>
          <Author ValidYN="Y">
            <LastName>Moy</LastName>
            <ForeName>Junlone</ForeName>
            <Initials>J</Initials>
            <AffiliationInfo>
              <Affiliation>Department of Pharmacy Practice, College of Pharmacy, University of Illinois Chicago, Chicago, Illinois, USA.</Affiliation>
            </AffiliationInfo>
          </Author>
          <Author ValidYN="Y">
            <LastName>Hirsch</LastName>
            <ForeName>Elizabeth B</ForeName>
            <Initials>EB</Initials>
            <Identifier Source="ORCID">0000-0002-0462-0421</Identifier>
            <AffiliationInfo>
              <Affiliation>Department of Experimental and Clinical Pharmacology, College of Pharmacy, University of Minnesota, Minneapolis, Minnesota, USA.</Affiliation>
            </AffiliationInfo>
          </Author>
          <Author ValidYN="Y">
            <LastName>Federle</LastName>
            <ForeName>Michael J</ForeName>
            <Initials>MJ</Initials>
            <Identifier Source="ORCID">0000-0002-4554-543X</Identifier>
            <AffiliationInfo>
              <Affiliation>Department of Pharmaceutical Sciences, College of Pharmacy, University of Illinois Chicago, Chicago, Illinois, USA.</Affiliation>
            </AffiliationInfo>
          </Author>
          <Author ValidYN="Y">
            <LastName>Flowers</LastName>
            <ForeName>Stephanie A</ForeName>
            <Initials>SA</Initials>
            <Identifier Source="ORCID">0000-0001-5149-9444</Identifier>
            <AffiliationInfo>
              <Affiliation>Department of Pharmacy Practice, College of Pharmacy, University of Illinois Chicago, Chicago, Illinois, USA.</Affiliation>
            </AffiliationInfo>
          </Author>
        </AuthorList>
        <Language>eng</Language>
        <GrantList CompleteYN="Y">
          <Grant>
            <GrantID>R01 AI091779</GrantID>
            <Acronym>AI</Acronym>
            <Agency>NIAID NIH HHS</Agency>
            <Country>United States</Country>
          </Grant>
        </GrantList>
        <PublicationTypeList>
          <PublicationType UI="D016428">Journal Article</PublicationType>
        </PublicationTypeList>
        <ArticleDate DateType="Electronic">
          <Year>2022</Year>
          <Month>04</Month>
          <Day>13</Day>
        </ArticleDate>
      </Article>
      <MedlineJournalInfo>
        <MedlineTA>J Bacteriol</MedlineTA>
        <NlmUniqueID>2985120R</NlmUniqueID>
        <ISSNLinking>0021-9193</ISSNLinking>
      </MedlineJournalInfo>
      <ChemicalList>
        <Chemical>
          <RegistryNumber>0</RegistryNumber>
          <NameOfSubstance UI="D000900">Anti-Bacterial Agents</NameOfSubstance>
        </Chemical>
        <Chemical>
          <RegistryNumber>0</RegistryNumber>
          <NameOfSubstance UI="D014150">Antipsychotic Agents</NameOfSubstance>
        </Chemical>
        <Chemical>
          <RegistryNumber>0</RegistryNumber>
          <NameOfSubstance UI="D029968">Escherichia coli Proteins</NameOfSubstance>
        </Chemical>
        <Chemical>
          <RegistryNumber>0</RegistryNumber>
          <NameOfSubstance UI="D012097">Repressor Proteins</NameOfSubstance>
        </Chemical>
        <Chemical>
          <RegistryNumber>2S3PL1B6UJ</RegistryNumber>
          <NameOfSubstance UI="D000069348">Quetiapine Fumarate</NameOfSubstance>
        </Chemical>
      </ChemicalList>
      <CitationSubset>IM</CitationSubset>
      <MeshHeadingList>
        <MeshHeading>
          <DescriptorName UI="D000900" MajorTopicYN="N">Anti-Bacterial Agents</DescriptorName>
          <QualifierName UI="Q000494" MajorTopicYN="N">pharmacology</QualifierName>
        </MeshHeading>
        <MeshHeading>
          <DescriptorName UI="D014150" MajorTopicYN="Y">Antipsychotic Agents</DescriptorName>
          <QualifierName UI="Q000494" MajorTopicYN="N">pharmacology</QualifierName>
        </MeshHeading>
        <MeshHeading>
          <DescriptorName UI="D004352" MajorTopicYN="N">Drug Resistance, Microbial</DescriptorName>
          <QualifierName UI="Q000235" MajorTopicYN="N">genetics</QualifierName>
        </MeshHeading>
        <MeshHeading>
          <DescriptorName UI="D004926" MajorTopicYN="N">Escherichia coli</DescriptorName>
          <QualifierName UI="Q000235" MajorTopicYN="N">genetics</QualifierName>
        </MeshHeading>
        <MeshHeading>
          <DescriptorName UI="D004927" MajorTopicYN="Y">Escherichia coli Infections</DescriptorName>
          <QualifierName UI="Q000188" MajorTopicYN="N">drug therapy</QualifierName>
        </MeshHeading>
        <MeshHeading>
          <DescriptorName UI="D029968" MajorTopicYN="Y">Escherichia coli Proteins</DescriptorName>
          <QualifierName UI="Q000235" MajorTopicYN="N">genetics</QualifierName>
        </MeshHeading>
        <MeshHeading>
          <DescriptorName UI="D006801" MajorTopicYN="N">Humans</DescriptorName>
        </MeshHeading>
        <MeshHeading>
          <DescriptorName UI="D008826" MajorTopicYN="N">Microbial Sensitivity Tests</DescriptorName>
        </MeshHeading>
        <MeshHeading>
          <DescriptorName UI="D000069348" MajorTopicYN="N">Quetiapine Fumarate</DescriptorName>
          <QualifierName UI="Q000494" MajorTopicYN="N">pharmacology</QualifierName>
          <QualifierName UI="Q000627" MajorTopicYN="N">therapeutic use</QualifierName>
        </MeshHeading>
        <MeshHeading>
          <DescriptorName UI="D012097" MajorTopicYN="N">Repressor Proteins</DescriptorName>
          <QualifierName UI="Q000235" MajorTopicYN="N">genetics</QualifierName>
        </MeshHeading>
      </MeshHeadingList>
      <KeywordList Owner="NOTNLM">
        <Keyword MajorTopicYN="N">antimicrobial resistance</Keyword>
        <Keyword MajorTopicYN="N">atypical antipsychotics</Keyword>
      </KeywordList>
      <CoiStatement>The authors declare a conflict of interest. E.B.H. has received grant funding from Merck and advisory board honoraria from Merck, MeMed, and Melinta.</CoiStatement>
    </MedlineCitation>
    <PubmedData>
      <History>
        <PubMedPubDate PubStatus="pmc-release">
          <Year>2022</Year>
          <Month>10</Month>
          <Day>13</Day>
        </PubMedPubDate>
        <PubMedPubDate PubStatus="pubmed">
          <Year>2022</Year>
          <Month>4</Month>
          <Day>14</Day>
          <Hour>6</Hour>
          <Minute>0</Minute>
        </PubMedPubDate>
        <PubMedPubDate PubStatus="medline">
          <Year>2022</Year>
          <Month>5</Month>
          <Day>20</Day>
          <Hour>6</Hour>
          <Minute>0</Minute>
        </PubMedPubDate>
        <PubMedPubDate PubStatus="entrez">
          <Year>2022</Year>
          <Month>4</Month>
          <Day>13</Day>
          <Hour>12</Hour>
          <Minute>12</Minute>
        </PubMedPubDate>
      </History>
      <PublicationStatus>ppublish</PublicationStatus>
      <ArticleIdList>
        <ArticleId IdType="pubmed">35416690</ArticleId>
        <ArticleId IdType="pmc">PMC9112998</ArticleId>
        <ArticleId IdType="doi">10.1128/jb.00102-22</ArticleId>
      </ArticleIdList>
      <ReferenceList>
        <Reference>
          <Citation>Centers for Disease Control and Prevention. 2019. Antibiotic resistance threats in the United States, 2019.
Centers for Disease Control and Prevention, Atlanta, GA.</Citation>
        </Reference>
        <Reference>
          <Citation>Maier L, Pruteanu M, Kuhn M, Zeller G, Telzerow A, Anderson EE, Brochado AR, Fernandez KC, Dose H, Mori H, Patil KR, Bork P, Typas A. 2018. Extensive impact of non-antibiotic drugs on human gut bacteria. Nature
555:623–628. doi:10.1038/nature25979.</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.1038/nature25979</ArticleId>
            <ArticleId IdType="pmc">PMC6108420</ArticleId>
            <ArticleId IdType="pubmed">29555994</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Jin M, Lu J, Chen Z, Nguyen SH, Mao L, Li J, Yuan Z, Guo J. 2018. Antidepressant fluoxetine induces multiple antibiotics resistance in Escherichia coli via ROS-mediated mutagenesis. Environ Int
120:421–430. doi:10.1016/j.envint.2018.07.046.</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.1016/j.envint.2018.07.046</ArticleId>
            <ArticleId IdType="pubmed">30125859</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Keepers GA, Fochtmann LJ, Anzia JM, Benjamin S, Lyness JM, Mojtabai R, Servis M, Walaszek A, Buckley P, Lenzenweger MF, Young AS, Degenhardt A, Hong S-H. 2020. The American Psychiatric Association practice guideline for the treatment of patients with schizophrenia. Am J Psychiatry
177:868–872. doi:10.1176/appi.ajp.2020.177901.</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.1176/appi.ajp.2020.177901</ArticleId>
            <ArticleId IdType="pubmed">32867516</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Sohn M, Moga DC, Blumenschein K, Talbert J. 2016. National trends in off-label use of atypical antipsychotics in children and adolescents in the United States. Medicine (Baltimore, MD)
95:e3784. doi:10.1097/MD.0000000000003784.</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.1097/MD.0000000000003784</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Dennis JA, Gittner LS, Payne JD, Nugent K. 2020. Characteristics of U.S. adults taking prescription antipsychotic medications, National Health and Nutrition Examination Survey 2013–2018. BMC Psychiatry
20:483. doi:10.1186/s12888-020-02895-4.</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.1186/s12888-020-02895-4</ArticleId>
            <ArticleId IdType="pmc">PMC7528276</ArticleId>
            <ArticleId IdType="pubmed">33004022</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Arnold MJ, Moody AL. 2018. Atypical antipsychotics for disruptive behavior disorders in children and adolescents. Am Fam Physician
97:715–716.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pubmed">30215931</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>De Fazio P, Manfredi V, Gareri P, Bruni A, Ciambrone P, Cerminara G, De Sarro G, Segura Garcia C. 2014. Use of atypical antipsychotics in the elderly: a clinical review. Clin Interv Aging
9:1363–1373. doi:10.2147/CIA.S63942.</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.2147/CIA.S63942</ArticleId>
            <ArticleId IdType="pmc">PMC4144926</ArticleId>
            <ArticleId IdType="pubmed">25170260</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Epstein RA, Bobo WV, Shelton RC, Arbogast PG, Morrow JA, Wang W, Chandrasekhar R, Cooper WO. 2013. Increasing use of atypical antipsychotics and anticonvulsants during pregnancy. Pharmacoepidemiol Drug Saf
22:794–801. doi:10.1002/pds.3366.</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.1002/pds.3366</ArticleId>
            <ArticleId IdType="pmc">PMC3888313</ArticleId>
            <ArticleId IdType="pubmed">23124892</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Logarinho F, Rosado T, Lourenço C, Barroso M, Araujo ARTS, Gallardo E. 2016. Determination of antipsychotic drugs in hospital and wastewater treatment plant samples by gas chromatography/tandem mass spectrometry. J Chromatogr B Analyt Technol Biomed Life Sci
1038:127–135. doi:10.1016/j.jchromb.2016.10.031.</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.1016/j.jchromb.2016.10.031</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Reichert JF, Souza DM, Martins AF. 2019. Antipsychotic drugs in hospital wastewater and a preliminary risk assessment. Ecotoxicol Environ Saf
170:559–567. doi:10.1016/j.ecoenv.2018.12.021.</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.1016/j.ecoenv.2018.12.021</ArticleId>
            <ArticleId IdType="pubmed">30576891</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Subedi B, Kannan K. 2015. Occurrence and fate of select psychoactive pharmaceuticals and antihypertensives in two wastewater treatment plants in New York State, USA. Sci Total Environ
514:273–280. doi:10.1016/j.scitotenv.2015.01.098.</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.1016/j.scitotenv.2015.01.098</ArticleId>
            <ArticleId IdType="pubmed">25666287</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Amaral L, Viveiros M, Molnar J. 2004. Antimicrobial activity of phenothiazines. In Vivo
18:725–731.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pubmed">15646813</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Andersson JA, Fitts EC, Kirtley ML, Ponnusamy D, Peniche AG, Dann SM, Motin VL, Chauhan S, Rosenzweig JA, Sha J, Chopra AK. 2016. New role for FDA-approved drugs in combating antibiotic-resistant bacteria. Antimicrob Agents Chemother
60:3717–3729. doi:10.1128/AAC.00326-16.</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.1128/AAC.00326-16</ArticleId>
            <ArticleId IdType="pmc">PMC4879411</ArticleId>
            <ArticleId IdType="pubmed">27067323</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Thanacoody HKR. 2007. Thioridazine: resurrection as an antimicrobial agent?
Br J Clin Pharmacol
64:566–574. doi:10.1111/j.1365-2125.2007.03021.x.</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.1111/j.1365-2125.2007.03021.x</ArticleId>
            <ArticleId IdType="pmc">PMC2203271</ArticleId>
            <ArticleId IdType="pubmed">17764469</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Nehme H, Saulnier P, Ramadan AA, Cassisa V, Guillet C, Eveillard M, Umerska A. 2018. Antibacterial activity of antipsychotic agents, their association with lipid nanocapsules and its impact on the properties of the nanocarriers and on antibacterial activity. PLoS One
13:e0189950. doi:10.1371/journal.pone.0189950.</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.1371/journal.pone.0189950</ArticleId>
            <ArticleId IdType="pmc">PMC5752010</ArticleId>
            <ArticleId IdType="pubmed">29298353</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Richtand NM, Welge JA, Logue AD, Keck PE, Strakowski SM, McNamara RK. 2007. Dopamine and serotonin receptor binding and antipsychotic efficacy. Neuropsychopharmacology
32:1715–1726. doi:10.1038/sj.npp.1301305.</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.1038/sj.npp.1301305</ArticleId>
            <ArticleId IdType="pubmed">17251913</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Flowers SA, Evans SJ, Ward KM, McInnis MG, Ellingrod VL. 2017. Interaction between atypical antipsychotics and the gut microbiome in a bipolar disease cohort. Pharmacotherapy
37:261–267. doi:10.1002/phar.1890.</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.1002/phar.1890</ArticleId>
            <ArticleId IdType="pubmed">28035686</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Flowers SA, Baxter NT, Ward KM, Kraal AZ, McInnis MG, Schmidt TM, Ellingrod VL. 2019. Effects of atypical antipsychotic treatment and resistant starch supplementation on gut microbiome composition in a cohort of patients with bipolar disorder or schizophrenia. Pharmacotherapy
39:161–170. doi:10.1002/phar.2214.</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.1002/phar.2214</ArticleId>
            <ArticleId IdType="pmc">PMC6386623</ArticleId>
            <ArticleId IdType="pubmed">30620405</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Davey KJ, O'Mahony SM, Schellekens H, O'Sullivan O, Bienenstock J, Cotter PD, Dinan TG, Cryan JF. 2012. Gender-dependent consequences of chronic olanzapine in the rat: effects on body weight, inflammatory, metabolic and microbiota parameters. Psychopharmacology (Berl)
221:155–169. doi:10.1007/s00213-011-2555-2.</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.1007/s00213-011-2555-2</ArticleId>
            <ArticleId IdType="pubmed">22234378</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Roberts R, Neasham A, Lambrinudi C, Khan A. 2018. A quantitative analysis of antipsychotic prescribing trends for the treatment of schizophrenia in England and Wales. JRSM Open
9:2054270418758570. doi:10.1177/2054270418758570.</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.1177/2054270418758570</ArticleId>
            <ArticleId IdType="pmc">PMC5912284</ArticleId>
            <ArticleId IdType="pubmed">29707225</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Højlund M, Pottegård A, Johnsen E, Kroken RA, Reutfors J, Munk‐Jørgensen P, Correll CU. 2019. Trends in utilization and dosing of antipsychotic drugs in Scandinavia: comparison of 2006 and 2016. Br J Clin Pharmacol
85:1598–1606. doi:10.1111/bcp.13945.</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.1111/bcp.13945</ArticleId>
            <ArticleId IdType="pmc">PMC6595354</ArticleId>
            <ArticleId IdType="pubmed">30927284</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>DeVane CL, Nemeroff CB. 2001. Clinical pharmacokinetics of quetiapine: an atypical antipsychotic. Clin Pharmacokinet
40:509–522. doi:10.2165/00003088-200140070-00003.</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.2165/00003088-200140070-00003</ArticleId>
            <ArticleId IdType="pubmed">11510628</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>López-Muñoz F, Álamo C. 2013. Active metabolites as antidepressant drugs: the role of norquetiapine in the mechanism of action of quetiapine in the treatment of mood disorders. Front Psychiatry
4:102. doi:10.3389/fpsyt.2013.00102.</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.3389/fpsyt.2013.00102</ArticleId>
            <ArticleId IdType="pmc">PMC3770982</ArticleId>
            <ArticleId IdType="pubmed">24062697</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Conway JR, Lex A, Gehlenborg N. 2017. UpSetR: an R package for the visualization of intersecting sets and their properties. Bioinformatics
33:2938–2940. doi:10.1093/bioinformatics/btx364.</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.1093/bioinformatics/btx364</ArticleId>
            <ArticleId IdType="pmc">PMC5870712</ArticleId>
            <ArticleId IdType="pubmed">28645171</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Alcock BP, Raphenya AR, Lau TTY, Tsang KK, Bouchard M, Edalatmand A, Huynh W, Nguyen A-LV, Cheng AA, Liu S, Min SY, Miroshnichenko A, Tran H-K, Werfalli RE, Nasir JA, Oloni M, Speicher DJ, Florescu A, Singh B, Faltyn M, Hernandez-Koutoucheva A, Sharma AN, Bordeleau E, Pawlowski AC, Zubyk HL, Dooley D, Griffiths E, Maguire F, Winsor GL, Beiko RG, Brinkman FSL, Hsiao WWL, Domselaar GV, McArthur AG. 2020. CARD 2020: antibiotic resistome surveillance with the Comprehensive Antibiotic Resistance Database. Nucleic Acids Res
48:D517–D525. doi:10.1093/nar/gkz935.</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.1093/nar/gkz935</ArticleId>
            <ArticleId IdType="pmc">PMC7145624</ArticleId>
            <ArticleId IdType="pubmed">31665441</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Sharma P, Haycocks JRJ, Middlemiss AD, Kettles RA, Sellars LE, Ricci V, Piddock LJV, Grainger DC. 2017. The multiple antibiotic resistance operon of enteric bacteria controls DNA repair and outer membrane integrity. Nat Commun
8:1444. doi:10.1038/s41467-017-01405-7.</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.1038/s41467-017-01405-7</ArticleId>
            <ArticleId IdType="pmc">PMC5684230</ArticleId>
            <ArticleId IdType="pubmed">29133912</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Cohen SP, McMurry LM, Levy SB. 1988. marA locus causes decreased expression of OmpF porin in multiple-antibiotic-resistant (Mar) mutants of Escherichia coli. J Bacteriol
170:5416–5422. doi:10.1128/jb.170.12.5416-5422.1988.</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.1128/jb.170.12.5416-5422.1988</ArticleId>
            <ArticleId IdType="pmc">PMC211632</ArticleId>
            <ArticleId IdType="pubmed">2848006</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Praski Alzrigat L, Huseby DL, Brandis G, Hughes D. 2017. Fitness cost constrains the spectrum of marR mutations in ciprofloxacin-resistant Escherichia coli. J Antimicrob Chemother
72:3016–3024. doi:10.1093/jac/dkx270.</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.1093/jac/dkx270</ArticleId>
            <ArticleId IdType="pmc">PMC5890708</ArticleId>
            <ArticleId IdType="pubmed">28962020</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Casaz P, Garrity-Ryan LK, McKenney D, Jackson C, Levy SB, Tanaka SK, Alekshun MN. 2006. MarA, SoxS and Rob function as virulence factors in an Escherichia coli murine model of ascending pyelonephritis. Microbiology (Reading)
152:3643–3650. doi:10.1099/mic.0.2006/000604-0.</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.1099/mic.0.2006/000604-0</ArticleId>
            <ArticleId IdType="pubmed">17159217</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Huseby DL, Pietsch F, Brandis G, Garoff L, Tegehall A, Hughes D. 2017. Mutation supply and relative fitness shape the genotypes of ciprofloxacin-resistant Escherichia coli. Mol Biol Evol
34:1029–1039. doi:10.1093/molbev/msx052.</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.1093/molbev/msx052</ArticleId>
            <ArticleId IdType="pmc">PMC5400412</ArticleId>
            <ArticleId IdType="pubmed">28087782</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Igler C, Rolff J, Regoes R. 2021. Multi-step vs. single-step resistance evolution under different drugs, pharmacokinetics, and treatment regimens. Elife
10:e64116. doi:10.7554/eLife.64116.</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.7554/eLife.64116</ArticleId>
            <ArticleId IdType="pmc">PMC8184216</ArticleId>
            <ArticleId IdType="pubmed">34001313</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Husain F, Nikaido H. 2010. Substrate path in the AcrB multidrug efflux pump of Escherichia coli: substrate path in AcrB. Mol Microbiol
78:320–330. doi:10.1111/j.1365-2958.2010.07330.x.</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.1111/j.1365-2958.2010.07330.x</ArticleId>
            <ArticleId IdType="pmc">PMC3008161</ArticleId>
            <ArticleId IdType="pubmed">20804453</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Blair JMA, Bavro VN, Ricci V, Modi N, Cacciotto P, Kleinekathöfer U, Ruggerone P, Vargiu AV, Baylay AJ, Smith HE, Brandon Y, Galloway D, Piddock LJV. 2015. AcrB drug-binding pocket substitution confers clinically relevant resistance and altered substrate specificity. Proc Natl Acad Sci USA
112:3511–3516. doi:10.1073/pnas.1419939112.</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.1073/pnas.1419939112</ArticleId>
            <ArticleId IdType="pmc">PMC4371985</ArticleId>
            <ArticleId IdType="pubmed">25737552</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Anes J, McCusker MP, Fanning S, Martins M. 2015. The ins and outs of RND efflux pumps in Escherichia coli. Front Microbiol
6:587. doi:10.3389/fmicb.2015.00587.</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.3389/fmicb.2015.00587</ArticleId>
            <ArticleId IdType="pmc">PMC4462101</ArticleId>
            <ArticleId IdType="pubmed">26113845</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Blair JMA, Smith HE, Ricci V, Lawler AJ, Thompson LJ, Piddock LJV. 2015. Expression of homologous RND efflux pump genes is dependent upon AcrB expression: implications for efflux and virulence inhibitor design. J Antimicrob Chemother
70:424–431. doi:10.1093/jac/dku380.</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.1093/jac/dku380</ArticleId>
            <ArticleId IdType="pmc">PMC4291234</ArticleId>
            <ArticleId IdType="pubmed">25288678</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Warner DM, Shafer WM, Jerse AE. 2008. Clinically relevant mutations that cause derepression of the Neisseria gonorrhoeae MtrC-MtrD-MtrE efflux pump system confer different levels of antimicrobial resistance and in vivo fitness. Mol Microbiol
70:462–478. doi:10.1111/j.1365-2958.2008.06424.x.</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.1111/j.1365-2958.2008.06424.x</ArticleId>
            <ArticleId IdType="pmc">PMC2602950</ArticleId>
            <ArticleId IdType="pubmed">18761689</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Westfahl KM, Merten JA, Buchaklian AH, Klug CS. 2008. Functionally important ATP binding and hydrolysis sites in Escherichia coli MsbA. Biochemistry
47:13878–13886. doi:10.1021/bi801745u.</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.1021/bi801745u</ArticleId>
            <ArticleId IdType="pmc">PMC2637178</ArticleId>
            <ArticleId IdType="pubmed">19053284</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Praski Alzrigat L, Huseby DL, Brandis G, Hughes D. 2021. Resistance/fitness trade-off is a barrier to the evolution of MarR inactivation mutants in Escherichia coli. J Antimicrob Chemother
76:77–83. doi:10.1093/jac/dkaa417.</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.1093/jac/dkaa417</ArticleId>
            <ArticleId IdType="pmc">PMC7729382</ArticleId>
            <ArticleId IdType="pubmed">33089314</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Woodford N, Ellington MJ. 2007. The emergence of antibiotic resistance by mutation. Clin Microbiol Infect
13:5–18. doi:10.1111/j.1469-0691.2006.01492.x.</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.1111/j.1469-0691.2006.01492.x</ArticleId>
            <ArticleId IdType="pubmed">17184282</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Martinez JL, Baquero F. 2000. Mutation frequencies and antibiotic resistance. Antimicrob Agents Chemother
44:1771–1777. doi:10.1128/AAC.44.7.1771-1777.2000.</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.1128/AAC.44.7.1771-1777.2000</ArticleId>
            <ArticleId IdType="pmc">PMC89960</ArticleId>
            <ArticleId IdType="pubmed">10858329</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Maslowska KH, Makiela‐Dzbenska K, Fijalkowska IJ. 2019. The SOS system: a complex and tightly regulated response to DNA damage. Environ Mol Mutagen
60:368–384. doi:10.1002/em.22267.</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.1002/em.22267</ArticleId>
            <ArticleId IdType="pmc">PMC6590174</ArticleId>
            <ArticleId IdType="pubmed">30447030</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Blázquez J, Rodríguez-Beltrán J, Matic I. 2018. Antibiotic-induced genetic variation: how it arises and how it can be prevented. Annu Rev Microbiol
72:209–230. doi:10.1146/annurev-micro-090817-062139.</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.1146/annurev-micro-090817-062139</ArticleId>
            <ArticleId IdType="pubmed">30200850</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Hao Z, Lou H, Zhu R, Zhu J, Zhang D, Zhao BS, Zeng S, Chen X, Chan J, He C, Chen PR. 2014. The multiple antibiotic resistance regulator MarR is a copper sensor in Escherichia coli. Nat Chem Biol
10:21–28. doi:10.1038/nchembio.1380.</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.1038/nchembio.1380</ArticleId>
            <ArticleId IdType="pubmed">24185215</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Ogundeji AO, Pohl CH, Sebolai OM. 2017. The repurposing of anti-psychotic drugs, quetiapine and olanzapine, as anti-cryptococcus drugs. Front Microbiol
8:815. doi:10.3389/fmicb.2017.00815.</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.3389/fmicb.2017.00815</ArticleId>
            <ArticleId IdType="pmc">PMC5422476</ArticleId>
            <ArticleId IdType="pubmed">28536567</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Maruoka N, Murata T, Omata N, Takashima Y, Tanii H, Yonekura Y, Fujibayashi Y, Wada Y. 2007. Effects of chlorpromazine on plasma membrane permeability and fluidity in the rat brain: a dynamic positron autoradiography and fluorescence polarization study. Prog Neuropsychopharmacol Biol Psychiatry
31:178–186. doi:10.1016/j.pnpbp.2006.08.019.</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.1016/j.pnpbp.2006.08.019</ArticleId>
            <ArticleId IdType="pubmed">17023107</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Pankiewicz-Dulacz M, Stenager E, Chen M, Stenager E. 2018. Incidence rates and risk of hospital registered infections among schizophrenia patients before and after onset of illness: a population-based nationwide register study. J Clin Med
7:485. doi:10.3390/jcm7120485.</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.3390/jcm7120485</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Lam YWF. 2018. Antipsychotic-associated urinary tract infections in the elderly. Brown Univ Psychopharmacol Update
29:2–3. doi:10.1002/pu.30360.</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.1002/pu.30360</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>van Strien AM, Souverein PC, Keijsers C, Karen JPW, Heerdink ER, Derijks H, Jeroen J, van Marum RJ. 2017. Antipsychotic drug use associated with urinary tract infections in older women. Maturitas
98:46–50. doi:10.1016/j.maturitas.2017.01.009.</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.1016/j.maturitas.2017.01.009</ArticleId>
            <ArticleId IdType="pubmed">28274327</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Dzahini O, Singh N, Taylor D, Haddad P. 2018. Antipsychotic drug use and pneumonia: systematic review and meta-analysis. J Psychopharmacol
32:1167–1181. doi:10.1177/0269881118795333.</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.1177/0269881118795333</ArticleId>
            <ArticleId IdType="pubmed">30334664</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Tolppanen A-M, Koponen M, Tanskanen A, Lavikainen P, Sund R, Tiihonen J, Hartikainen S, Taipale H. 2016. Antipsychotic use and risk of hospitalization or death due to pneumonia in persons with and those without Alzheimer disease. Chest
150:1233–1241. doi:10.1016/j.chest.2016.06.004.</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.1016/j.chest.2016.06.004</ArticleId>
            <ArticleId IdType="pubmed">27298071</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Humphries RM, Ambler J, Mitchell SL, Castanheira M, Dingle T, Hindler JA, Koeth L, Sei K. 2018. CLSI Methods Development and Standardization Working Group best practices for evaluation of antimicrobial susceptibility tests. J Clin Microbiol
56:e01934-17. doi:10.1128/JCM.01934-17.</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.1128/JCM.01934-17</ArticleId>
            <ArticleId IdType="pmc">PMC5869819</ArticleId>
            <ArticleId IdType="pubmed">29367292</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Deatherage DE, Barrick JE. 2014. Identification of mutations in laboratory-evolved microbes from next-generation sequencing data using breseq. Methods Mol Biol
1151:165–188. doi:10.1007/978-1-4939-0554-6_12.</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.1007/978-1-4939-0554-6_12</ArticleId>
            <ArticleId IdType="pmc">PMC4239701</ArticleId>
            <ArticleId IdType="pubmed">24838886</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Thomason LC, Sawitzke JA, Li X, Costantino N, Court DL. 2014. Recombineering: genetic engineering in bacteria using homologous recombination. Curr Protoc Mol Biol
106:1.16.1–1.16.39. doi:10.1002/0471142727.mb0116s106.</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.1002/0471142727.mb0116s106</ArticleId>
            <ArticleId IdType="pubmed">24733238</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Datsenko KA, Wanner BL. 2000. One-step inactivation of chromosomal genes in Escherichia coli K-12 using PCR products. Proc Natl Acad Sci USA
97:6640–6645. doi:10.1073/pnas.120163297.</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.1073/pnas.120163297</ArticleId>
            <ArticleId IdType="pmc">PMC18686</ArticleId>
            <ArticleId IdType="pubmed">10829079</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Tu Q, Yin J, Fu J, Herrmann J, Li Y, Yin Y, Stewart AF, Müller R, Zhang Y. 2016. Room temperature electrocompetent bacterial cells improve DNA transformation and recombineering efficiency. Sci Rep
6:24648. doi:10.1038/srep24648.</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.1038/srep24648</ArticleId>
            <ArticleId IdType="pmc">PMC4837392</ArticleId>
            <ArticleId IdType="pubmed">27095488</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Sprouffske K, Wagner A. 2016. Growthcurver: an R package for obtaining interpretable metrics from microbial growth curves. BMC Bioinformatics
17:172. doi:10.1186/s12859-016-1016-7.</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.1186/s12859-016-1016-7</ArticleId>
            <ArticleId IdType="pmc">PMC4837600</ArticleId>
            <ArticleId IdType="pubmed">27094401</ArticleId>
          </ArticleIdList>
        </Reference>
      </ReferenceList>
    </PubmedData>
  </PubmedArticle>
</PubmedArticleSet>
